Yahuilong announced that the company has received six medical device registration certificates for microfluidic chemiluminescence detection reagents from the Guangdong Medical Products Administration. These certificates are part of the key special project on diagnostic and therapeutic equipment and biomedical materials under the national key research and development program of the 14th Five-Year Plan, for which the company serves as the project lead. They mainly include high-sensitivity troponin I assay kit, N-terminal pro-B-type natriuretic peptide assay kit, creatine kinase isoenzyme assay kit, myoglobin assay kit, B-type natriuretic peptide assay kit, and D-dimer assay kit. The registration certificates are valid until 2031 and are primarily used for auxiliary diagnosis of diseases such as myocardial infarction and heart failure. In the first quarter of 2026, Yahuilong achieved revenue of 398 million yuan and net profit attributable to the parent company of 17.95 million yuan.
Shenzhen YHLO Biotech Co. Ltd. AObtained six medical device registration certificates for microfluidic chemiluminescence reagents, enabling product commercialization.